The most consequential number on Embody’s website may not be its advertised $69 monthly price. It may be the amount collected at checkout, the renewal charge that follows, or the portion of a bundle that remains nonrefundable after cancellation. For adults comparing GLP-1 programs, those numbers belong together. Embody’s public materials provide several specific prices, but they do not establish a single, reconciled offer connecting the homepage advertisement to a particular medication, payment schedule and commitment.
Embody, also called JoinEm, presents itself as a weight-management platform operated by Modern Metabolic Medicine, Inc., with treatment provided through OpenLoop Health and prescriptions fulfilled by independent pharmacies. This documentary review examines sources consulted October 19, 2026, rather than a purchased treatment experience. Its central finding is practical: Embody documents a bundled care model and multiple subscription options, but shoppers need a written, plan-specific explanation of the first charge, later charges and cancellation deadline before treating any advertised monthly amount as their budget.
At a glance
- Homepage prices
- The homepage advertises GLP-1 injections at $69/month and GLP-1/GIP injections at $119/month; the supplied materials do not reconcile those offers with the terms’ pricing tables.
- Introductory pricing
- Embody Start lists semaglutide injection at $99 for month one, then $299/month, and tirzepatide injection at $149 for month one, then $399/month.Sources: [5]
- Bundle pricing
- Embody Flat lists semaglutide injection at $199/month monthly, or monthly rates of $169, $159 and $149 for three-, six- and twelve-month bundles; the collection schedule is not established.Sources: [5]
- Cancellation deadline
- The specific policy requires cancellation requests at least 72 hours before the next billing date, unlike the homepage’s shipment-based explanation.
- Refund boundary
- Payments are generally final at purchase. Medical disqualification has a partial-refund exception for the unused portion of the current term, with used services deducted.Sources: [6]
Start with the checkout amount, not the banner
Embody’s homepage presents GLP-1 injections at a “flat rate” of $69/month and GLP-1/GIP injections at $119/month. Both cards describe weekly injections, delivery to the customer’s door and no hidden fees. However, the cards do not identify the active ingredient, total plan price or commitment supporting those figures. The terms describe different Start and Flat prices. That discrepancy is not a reason to erase the advertised numbers, but it prevents presenting them as universally available, fully explained offers.
A separate Pre-Black Friday banner advertises $200 in immediate savings plus fast, free shipping. The supplied text does not identify the eligible plan, requirements or expiration. Nor does it show how the promotion interacts with the $69 and $119 cards. The useful question is therefore not simply whether a discount exists, but which exact product and subscription receive it, what is collected now, and what replaces that charge later.
The terms authorize an initial charge at purchase and automatic recurring charges according to the selected plan until cancellation. They do not settle whether every bundle is collected entirely upfront or under another schedule. Ask for the checkout total and renewal schedule together, rather than inferring either from a monthly equivalent. Our guide to why the first payment can differ from the advertised monthly price explains the distinction to preserve when comparing quotes.
| Product and presentation | First month | Month two onward |
|---|---|---|
| Semaglutide injection | $99 | $299/month |
| Semaglutide gum | $149 | $349/month |
| Tirzepatide injection | $149 | $399/month |
| Tirzepatide gum | $199 | $449/month |
Start and Flat are materially different price structures
Embody Start explicitly uses a reduced first-month price followed by standard monthly pricing beginning in month two. Its injectable semaglutide offer moves from $99 to $299/month, while injectable tirzepatide moves from $149 to $399/month. The terms also list semaglutide gum at $149 initially and $349/month afterward, and tirzepatide gum at $199 initially and $449/month afterward. The supplied documentation does not confirm the gums’ specific formulation, availability or presentation-specific safety information.
Embody Flat is described differently: fixed monthly pricing that does not increase over time, with optional commitment-based discounts. For semaglutide injection, the listed rate is $199/month on a monthly arrangement, $169/month for a three-month bundle, $159/month for six months and $149/month for twelve months. The terms also list adjustments of $50/month for semaglutide gum, $100/month for tirzepatide injection and $50/month for tirzepatide gum. Their precise application is not sufficiently explained to construct definitive alternative-product quotes.
The homepage FAQ says price does not rise when the dose changes within the same medication, but that statement does not cancel Start’s scheduled second-month increase. The FAQ also refers to 4-, 12-, 24- and 52-week plans, whereas the terms describe bundles in months. Four weeks is not a calendar month, and a package’s duration does not establish medication quantity. Get the selected interval, supply and commitment in writing; our billing-cycle explanation covers why these labels should not be treated as interchangeable.
What the bundled price actually promises
Embody says medication is included in the program cost. Its subscription policy describes a single bundled price covering access to healthcare providers, medications when clinically appropriate, laboratory services when applicable, online support and related care services. Those conditions matter: the policy does not promise every medication to every subscriber or establish a universal laboratory schedule. It also says the price is not itemized by individual service, visit, shipment or month, with no separately refundable component.
The homepage advertises unlimited appointments, messaging as often as needed and access to a specialist team around the clock. Optional care coaching is described as free and unnecessary for receiving medication. Embody expressly distinguishes those coaches from clinicians: their role is education, motivation and accountability. These are useful documented features, but round-the-clock support does not establish a clinician-response deadline or a required cadence of clinical follow-up. Those operational details remain relevant to the value of the subscription.
Embody also markets direct access without insurance approvals, denials or delays. That language does not confirm insurance acceptance, medication coverage or reimbursement. The reviewed materials likewise do not establish HSA/FSA conditions. A prospective member should separate the program’s quoted price from any hoped-for reimbursement and ask which services are conditional. The broader checklist in what a GLP-1 program price includes is useful here because an inclusive marketing phrase is not the same as a fully specified service schedule.
Payment comes before the documented prescribing decision
The contact page promotes a two-minute assessment with no card required to find out whether someone qualifies. Elsewhere, Embody states that completing the assessment does not create a doctor-patient relationship with Embody. Its footer places the OpenLoop clinician’s prescription-eligibility determination after checkout and reserves prescribing decisions to those clinicians. Consequently, initial screening should not be confused with a guaranteed prescription or final clinical acceptance before payment.
The terms require users to be at least 18 and live in the United States in a state or territory where services are available. They say availability is limited to certain states and direct customers to support@joinem.co for the current list. The supplied sources do not provide that list or complete clinical eligibility criteria. Intake information may include current and past conditions, medications, blood pressure, diagnostic tests when applicable, location and demographic details.
Embody’s FAQ describes review after intake and documentation are submitted. If approved, the prescription goes to the pharmacy for fulfillment and shipment to the address on file; additional information may trigger a brief virtual appointment. Existing GLP-1 users can request a transfer and must provide proof of their current prescription for review. Neither a transfer request nor a completed assessment establishes approval, and the reviewed materials specify no numeric turnaround time for the clinical decision.
Separate the platform, clinical team and pharmacy
Modern Metabolic Medicine, Inc. is identified as Embody’s legal operator. The terms state that JoinEm does not provide healthcare services through the platform and is not licensed to practice medicine. Treatment is attributed to OpenLoop Health, described as an affiliated network of medical professional corporations and associations. This division matters financially as well as operationally: the company collecting a subscription, the clinician deciding on treatment and the pharmacy supplying medication have different responsibilities.
The terms assign prescription fulfillment and shipping to independent third-party pharmacies and carriers that Modern Metabolic Medicine does not own, operate or control. The site names Red Rock Compounding Pharmacy, Health Warehouse, Precision Medicine and Triad Rx as partners. It describes compounded prescriptions as prepared by state-licensed 503A pharmacies and says its partners conduct extensive quality testing. These are provider representations, not independent verification of licenses, testing results or the pharmacy that would serve a particular member.
Free expedited home delivery is advertised, but no numerical arrival deadline, shipment frequency, carrier or cold-chain process is established in the supplied materials. For administrative questions, Embody publishes support@joinem.co and (347) 269-4270 and says its care team is available 24/7. Personal treatment questions should go through the patient portal to reach the clinician. Asking who handles a delayed shipment, prescription question or billing dispute before paying can make these separate responsibilities more concrete.
Cancellation has a billing deadline, not just a shipment cutoff
The homepage says customers can cancel before their next medication shipment to avoid the upcoming charge; if the shipment has already been processed, cancellation begins with the following billing cycle. The specific cancellation policy instead requires the request to be received at least 72 hours before the next billing date. These are different triggers. A shipment that has not yet been processed does not, by itself, establish that the policy’s billing deadline remains open.
Under the specific policy, a request received inside that 72-hour window does not stop the current cycle’s charge. The charge is nonrefundable, and cancellation takes effect at the start of the subsequent billing cycle. Documented cancellation routes include email, telephone and the online account or patient portal. A useful preparation step is to obtain the next billing date and written confirmation of the effective cancellation date, rather than relying on a general promise that cancellation is available.
Multi-month bundles carry an additional boundary: the policy describes a discounted rate in exchange for a full-term commitment. It excludes refunds or credits for unused months, services, undelivered or unshipped medication and the remaining term, with no proration. Cancellation therefore should not be read as release from the purchased bundle or repayment of its unused portion. Our guide to cancellation and refunds explains the distinction between stopping future renewals and recovering money already committed.
The medical-disqualification exception is not a full-refund promise
Embody’s policy makes subscription payments final and nonrefundable at purchase, covering single-month, multi-month and bundled plans whether or not services have been used. Failure to complete intake, attend or finish a consultation, or fill or accept a prescription does not create a refund entitlement. Because the prescribing decision is documented as occurring after checkout, these terms deserve attention before payment rather than only after someone changes their mind.
There is a specific exception when the healthcare provider determines that a member is not clinically eligible. The subscription is canceled and the unused portion of the amount paid for the current term is refunded. However, the policy counts consultations, intake or record review, issued prescriptions, dispensed or shipped medication, and ordered or performed laboratory services among used services. It does not quantify those deductions, so a prospective customer cannot calculate a guaranteed refund from the supplied documents.
Delivery problems have their own remedy. Damaged items may be replaced by the pharmacy after evidence of damage is received; incorrect items are to be replaced. The policy identifies replacement, not a refund, as the sole remedy in both situations. Customers should ask how to report and document problems and which organization handles the replacement. These provisions should not be interpreted as a promise that every shipping complaint produces reimbursement or that an unused shipment is automatically refundable.
Product evidence and unresolved costs belong in the final comparison
Embody’s safety index includes compounded semaglutide and tirzepatide injections alongside information about Ozempic, Mounjaro and Rybelsus. An entry in that index does not establish that the branded product is sold or included in a quoted subscription. Embody also attributes its website benefit claims to self-reported customer data involving compounded GLP-1 treatment and professional consultations. Those statements are not independently measured outcomes for the platform or a basis for predicting an individual customer’s results.
FDA explains that compounded preparations are not approved and do not undergo its premarket review for safety, effectiveness and quality. Nonapproval alone does not establish clinical inequivalence. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. FDA also explicitly advises not using an injectable GLP-1 product that arrives warm or inadequately refrigerated and contacting the provider or dispensing pharmacy to resolve the concern.
For a final cost comparison, the unresolved items are specific: the homepage-price qualification, bundle collection schedule, exact medication and supply, gum adjustments, shipping frequency and medical-disqualification deductions. The supplied terms also contain an omitted intermediate section, limiting a complete contractual assessment. NIDDK notes that medication decisions involve benefits, side effects, health conditions, other medicines and costs. A usable Embody quote should support that clinical conversation, not replace it with the lowest advertised monthly number.
Questions & answers
Can I assume I will pay Embody $69 each month?
No. The homepage advertises $69/month for GLP-1 injections, but the supplied materials do not connect that amount to a specific active ingredient, commitment, initial collection or supply. The terms list different Start and Flat prices. Ask Embody to identify the exact offer in your checkout and confirm the first charge, recurring charge, billing interval and full commitment before payment.
Does an Embody bundle have to be paid entirely upfront?
The supplied documents do not establish the collection schedule clearly enough to say that every bundle requires full upfront payment. They do establish a full-term commitment for multi-month bundles and exclude prorated refunds for unused portions. Request both the payment schedule and total contractual commitment; a displayed monthly rate alone does not answer either question.
What if I pay but the clinician says I am not eligible?
Embody’s policy provides cancellation and a refund of the unused portion of the current term when its healthcare provider determines clinical ineligibility. That is not necessarily a full refund. Intake review, consultations, issued prescriptions, dispensed or shipped medication and ordered or performed labs can count as used services. The documents do not provide amounts for those deductions.
When should I cancel to stop the next Embody charge?
The specific policy requires receipt of the request at least 72 hours before the next billing date. Inside that window, the policy allows the cycle’s nonrefundable charge and postpones cancellation to the next cycle. Although the homepage uses a shipment-based cutoff, do not assume shipment timing satisfies the billing rule. Cancellation is available through support email, telephone or the account/patient portal.
Does Embody serve my state, and can I transfer an existing prescription?
Embody requires adulthood and residence in an available U.S. state or territory, but the supplied sources do not list all supported locations. Contact support@joinem.co for the current state list. The platform welcomes transfer requests from existing GLP-1 users and asks for proof of the current prescription for professional review. That review does not guarantee acceptance or continuation of a particular prescription.
Who handles treatment questions and medication delivery?
Embody directs personal treatment questions through the patient portal to the clinician. Administrative support is listed at support@joinem.co and (347) 269-4270, with 24/7 availability advertised. Independent pharmacies and carriers fulfill and ship prescribed medication. Free expedited delivery does not establish an arrival deadline, and the supplied documents do not identify which partner pharmacy would serve a particular patient.
Our assessment
Embody documents more than a medication shipment: its subscription includes conditional medication and lab services, provider access, online support and optional free nonclinical coaching. It also publishes specific introductory and ongoing prices, named pharmacy partners and multiple contact routes. Those details give prospective customers useful questions to resolve. The principal cost weakness is that the homepage offers do not reconcile with the terms, while weeks-based plan descriptions and month-based bundles leave additional uncertainty. The cancellation policy’s 72-hour billing deadline and the broad nonrefundability of purchased terms make that uncertainty financially important. A sound decision requires a written quote identifying the exact product, initial collection, renewal amount, billing interval, supply and commitment, plus confirmation of the applicable cancellation rule. Without that clarification, the public materials are insufficient for a reliable personal budget. With it, customers can compare Embody’s documented service bundle and financial obligations rather than choosing on the banner price alone.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.
- FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
- NIDDK: prescription medications for overweight and obesity ↗
- Embody (joinem.co; también denominado JoinEm) — pages/contact ↗
- Embody (joinem.co; también denominado JoinEm) — pages/glp1_medication_safety_information ↗
- Embody (joinem.co; también denominado JoinEm) — pages/terms conditions ↗
- Embody (joinem.co; también denominado JoinEm) — pages/refund policy ↗
- Embody (joinem.co; también denominado JoinEm) — official website ↗